

# SAFETY DATA SHEET



MVP Total RNA - Human Adult Larynx - Disease Match Set, Part Number  
540075

## Section 1. Identification

**Product identifier** : MVP Total RNA - Human Adult Larynx - Disease Match Set, Part Number 540075  
**Part No. (Chemical Kit)** : 540075  
**Part No.** :  MVP Total RNA, Human Adult Larynx 540047-41  
MVP Total RNA Larynx Diseased Human Adult 540059-41

### Relevant identified uses of the substance or mixture and uses advised against

Analytical reagent.

MVP Total RNA, Human Adult Larynx 25 µg  
MVP Total RNA Larynx Diseased Human Adult 25 µg

**Supplier/Manufacturer** : Agilent Technologies Australia Pty Ltd  
679 Springvale Road  
Mulgrave  
Victoria 3170, Australia  
1800 802 402

**Emergency telephone number (with hours of operation)** : CHEMTREC®: +(61)-290372994

## Section 2. Hazard(s) identification

### Classification of the substance or mixture

Not classified.

### GHS label elements

**Signal word** :  MVP Total RNA, Human Adult Larynx No signal word.  
MVP Total RNA Larynx Diseased Human Adult No signal word.  
**Hazard statements** :  MVP Total RNA, Human Adult Larynx No known significant effects or critical hazards.  
MVP Total RNA Larynx Diseased Human Adult No known significant effects or critical hazards.

### Precautionary statements

**Prevention** :  MVP Total RNA, Human Adult Larynx Not applicable.  
MVP Total RNA Larynx Diseased Human Adult Not applicable.  
**Response** :  MVP Total RNA, Human Adult Larynx Not applicable.  
MVP Total RNA Larynx Diseased Human Adult Not applicable.  
**Storage** :  MVP Total RNA, Human Adult Larynx Not applicable.  
MVP Total RNA Larynx Diseased Human Adult Not applicable.  
**Disposal** :  MVP Total RNA, Human Adult Larynx Not applicable.  
MVP Total RNA Larynx Diseased Human Adult Not applicable.

## Section 2. Hazard(s) identification

### Supplemental label elements

<b>Additional warning phrases</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not applicable. Not applicable.
<b>Other hazards which do not result in classification</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	None known. None known.

## Section 3. Composition and ingredient information

<b>Substance/mixture</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Mixture Mixture
--------------------------	--	--------------------

### CAS number/other identifiers

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

## Section 4. First aid measures

### Description of necessary first aid measures

<b>Eye contact</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs. Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
<b>Inhalation</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
<b>Skin contact</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
<b>Ingestion</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur. Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical

## Section 4. First aid measures

attention if symptoms occur.

### Most important symptoms/effects, acute and delayed

#### Potential acute health effects

<b>Eye contact</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Inhalation</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Skin contact</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Ingestion</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

<b>Eye contact</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No specific data. No specific data.
<b>Inhalation</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No specific data. No specific data.
<b>Skin contact</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No specific data. No specific data.
<b>Ingestion</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No specific data. No specific data.

### Indication of immediate medical attention and special treatment needed, if necessary

<b>Notes to physician</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled. Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
<b>Specific treatments</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No specific treatment. No specific treatment.
<b>Protection of first-aiders</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No action shall be taken involving any personal risk or without suitable training. No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

## Section 5. Firefighting measures

### Extinguishing media

<b>Suitable extinguishing media</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Use an extinguishing agent suitable for the surrounding fire. Use an extinguishing agent suitable for the surrounding fire.
<b>Unsuitable extinguishing media</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	None known. None known.
<b>Specific hazards arising from the chemical</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	In a fire or if heated, a pressure increase will occur and the container may burst. In a fire or if heated, a pressure increase will occur and the container may burst.
<b>Hazardous thermal decomposition products</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No specific data. No specific data.
<b>Special protective actions for fire-fighters</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
<b>Special protective equipment for fire-fighters</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

## Section 6. Accidental release measures

### Personal precautions, protective equipment and emergency procedures

<b>For non-emergency personnel</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment. No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
<b>For emergency responders</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

## Section 6. Accidental release measures

<b>Environmental precautions</b>	: MVP Total RNA, Human Adult Larynx	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
	MVP Total RNA Larynx Diseased Human Adult	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### Methods and material for containment and cleaning up

<b>Methods for cleaning up</b>	: MVP Total RNA, Human Adult Larynx	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
	MVP Total RNA Larynx Diseased Human Adult	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

## Section 7. Handling and storage

### Precautions for safe handling

<b>Protective measures</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Put on appropriate personal protective equipment (see Section 8). Put on appropriate personal protective equipment (see Section 8).
<b>Advice on general occupational hygiene</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures. Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
<b>Conditions for safe storage, including any incompatibilities</b>	: MVP Total RNA, Human Adult Larynx  MVP Total RNA Larynx Diseased Human Adult	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use. Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and

## Section 7. Handling and storage

drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

## Section 8. Exposure controls and personal protection

### Control parameters

#### Occupational exposure limits

None.

- Appropriate engineering controls** : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### Individual protection measures

- Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

- Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

### Skin protection

- Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

- Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

- Respiratory protection** :  Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

## Section 9. Physical and chemical properties

### Appearance

- Physical state** :  MVP Total RNA, Human Adult Larynx Liquid.  
 MVP Total RNA Larynx Diseased Human Adult Liquid.
- Colour** :  MVP Total RNA, Human Adult Larynx Not available.  
 MVP Total RNA Larynx Diseased Human Adult Not available.

## Section 9. Physical and chemical properties

<b>Odour</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Odour threshold</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>pH</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	8 8
<b>Melting point</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	0°C (32°F) 0°C (32°F)
<b>Boiling point</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	100°C (212°F) 100°C (212°F)
<b>Flash point</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Evaporation rate</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Flammability (solid, gas)</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not applicable. Not applicable.
<b>Lower and upper explosive (flammable) limits</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Vapour pressure</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Vapour density</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Relative density</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Solubility</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Easily soluble in the following materials: cold water and hot water. Easily soluble in the following materials: cold water and hot water.
<b>Partition coefficient: n-octanol/water</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.
<b>Auto-ignition temperature</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	Not available. Not available.

## Section 9. Physical and chemical properties

<b>Decomposition temperature</b>	: MVP Total RNA, Human Adult Larynx	Not available.
	MVP Total RNA Larynx Diseased Human Adult	Not available.
<b>Viscosity</b>	: MVP Total RNA, Human Adult Larynx	Not available.
	MVP Total RNA Larynx Diseased Human Adult	Not available.

## Section 10. Stability and reactivity

<b>Reactivity</b>	: MVP Total RNA, Human Adult Larynx	No specific test data related to reactivity available for this product or its ingredients.
	MVP Total RNA Larynx Diseased Human Adult	No specific test data related to reactivity available for this product or its ingredients.
<b>Chemical stability</b>	: MVP Total RNA, Human Adult Larynx	The product is stable.
	MVP Total RNA Larynx Diseased Human Adult	The product is stable.
<b>Possibility of hazardous reactions</b>	: MVP Total RNA, Human Adult Larynx	Under normal conditions of storage and use, hazardous reactions will not occur.
	MVP Total RNA Larynx Diseased Human Adult	Under normal conditions of storage and use, hazardous reactions will not occur.
<b>Conditions to avoid</b>	: MVP Total RNA, Human Adult Larynx	No specific data.
	MVP Total RNA Larynx Diseased Human Adult	No specific data.
<b>Incompatible materials</b>	: MVP Total RNA, Human Adult Larynx	May react or be incompatible with oxidising materials.
	MVP Total RNA Larynx Diseased Human Adult	May react or be incompatible with oxidising materials.
<b>Hazardous decomposition products</b>	: MVP Total RNA, Human Adult Larynx	Under normal conditions of storage and use, hazardous decomposition products should not be produced.
	MVP Total RNA Larynx Diseased Human Adult	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## Section 11. Toxicological information

### Information on toxicological effects

#### Acute toxicity

Not available.

#### Irritation/Corrosion

Not available.

#### Sensitisation

Not available.

#### Mutagenicity

Not available.

#### Carcinogenicity

Not available.



## Section 11. Toxicological information

### Reproductive toxicity

Not available.

### Teratogenicity

Not available.

### Specific target organ toxicity (single exposure)

Not available.

### Specific target organ toxicity (repeated exposure)

Not available.

### Aspiration hazard

Not available.

**Information on likely routes of exposure** : MVP Total RNA, Human Adult Larynx Not available.  
MVP Total RNA Larynx Not available.  
Diseased Human Adult

### Potential acute health effects

**Eye contact** : MVP Total RNA, Human Adult Larynx No known significant effects or critical hazards.  
MVP Total RNA Larynx No known significant effects or critical hazards.  
Diseased Human Adult

**Inhalation** : MVP Total RNA, Human Adult Larynx No known significant effects or critical hazards.  
MVP Total RNA Larynx No known significant effects or critical hazards.  
Diseased Human Adult

**Skin contact** : MVP Total RNA, Human Adult Larynx No known significant effects or critical hazards.  
MVP Total RNA Larynx No known significant effects or critical hazards.  
Diseased Human Adult

**Ingestion** : MVP Total RNA, Human Adult Larynx No known significant effects or critical hazards.  
MVP Total RNA Larynx No known significant effects or critical hazards.  
Diseased Human Adult

### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : MVP Total RNA, Human Adult Larynx No specific data.  
MVP Total RNA Larynx No specific data.  
Diseased Human Adult

**Inhalation** : MVP Total RNA, Human Adult Larynx No specific data.  
MVP Total RNA Larynx No specific data.  
Diseased Human Adult

**Skin contact** : MVP Total RNA, Human Adult Larynx No specific data.  
MVP Total RNA Larynx No specific data.  
Diseased Human Adult

**Ingestion** : MVP Total RNA, Human Adult Larynx No specific data.  
MVP Total RNA Larynx No specific data.  
Diseased Human Adult

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

#### Short term exposure

## Section 11. Toxicological information

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

### Long term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

### Potential chronic health effects

Not available.

<b>General</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Carcinogenicity</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Mutagenicity</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Teratogenicity</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Developmental effects</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.
<b>Fertility effects</b>	: MVP Total RNA, Human Adult Larynx MVP Total RNA Larynx Diseased Human Adult	No known significant effects or critical hazards. No known significant effects or critical hazards.

### Numerical measures of toxicity

#### Acute toxicity estimates

Not available.

## Section 12. Ecological information

### Toxicity

Not available.

### Persistence and degradability

Not available.

### Bioaccumulative potential

Not available.

### Mobility in soil

**Soil/water partition coefficient (K<sub>oc</sub>)** : Not available.

## Section 12. Ecological information

**Other adverse effects** : No known significant effects or critical hazards.

## Section 13. Disposal considerations

**Disposal methods** : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## Section 14. Transport information

**ADG / IMDG / IATA** : Not regulated as Dangerous Goods according to the ADG Code .

**Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**Transport in bulk according to Annex II of Marpol and the IBC Code** : Not available.

## Section 15. Regulatory information

### Standard Uniform Schedule of Medicine and Poisons

Not regulated.

### Model Work Health and Safety Regulations - Scheduled Substances

No listed substance

### International regulations

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

#### Montreal Protocol (Annexes A, B, C, E)

Not listed.

#### Stockholm Convention on Persistent Organic Pollutants

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

### Inventory list

**Australia** : All components are listed or exempted.  
**Canada** : All components are listed or exempted.  
**China** : All components are listed or exempted.  
**Europe** : All components are listed or exempted.  
**Japan** : **Japan inventory (ENCS):** All components are listed or exempted.  
**Japan inventory (ISHL):** All components are listed or exempted.

## Section 15. Regulatory information

Malaysia	: Not determined.
New Zealand	: All components are listed or exempted.
Philippines	: All components are listed or exempted.
Republic of Korea	: All components are listed or exempted.
Taiwan	: All components are listed or exempted.
Thailand	: <input checked="" type="checkbox"/> Not determined.
Turkey	: <input checked="" type="checkbox"/> Not determined.
United States	: All components are listed or exempted.
Viet Nam	: <input checked="" type="checkbox"/> Not determined.

## Section 16. Any other relevant information

### History

Date of issue/Date of revision	: 29/12/2017
Date of previous issue	: 28/09/2015.
Version	: 4

### Key to abbreviations

ADG = Australian Dangerous Goods
ATE = Acute Toxicity Estimate
BCF = Bioconcentration Factor
GHS = Globally Harmonized System of Classification and Labelling of Chemicals
IATA = International Air Transport Association
IBC = Intermediate Bulk Container
IMDG = International Maritime Dangerous Goods
LogPow = logarithm of the octanol/water partition coefficient
MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
NOHSC = National Occupational Health and Safety Commission
SUSMP = Standard Uniform Schedule of Medicine and Poisons
UN = United Nations

### Procedure used to derive the classification

Classification	Justification
Not classified.	

References : Not available.

Indicates information that has changed from previously issued version.

### Notice to reader

**Disclaimer:** The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.